Payment overview · 2025
General Payments
$54,972.21
110 reported records · 16 companies
Healthcare provider profile · identity verified
Aaron J. Chokan, DPM
Podiatric Medicine & Surgery Service Providers|Podiatrist|Foot & Ankle Surgery · STOW, OH · NPI 1700888401
Verified facts
What the public records show
CMS Open Payments records show Aaron J. Chokan, DPM received $54,972.21 in general payments during 2025 across 110 reported records.
TREACE MEDICAL CONCEPTS, INC. accounted for 92.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $50,548.77 | 92.0% | 73 | 2025 |
| Aroa Biosurgery Incorporated | Unresolved — no canonical attribution shown | $3,416.22 | 6.2% | 15 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $263.41 | 0.5% | 2 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $188.20 | 0.3% | 3 | 2025 |
| restor3d, inc. | Unresolved — no canonical attribution shown | $122.31 | 0.2% | 1 | 2025 |
| EBI, LLC | Unresolved — no canonical attribution shown | $86.22 | 0.2% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.89 | 0.2% | 4 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $39.80 | 0.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.00 | 0.1% | 2 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $34.71 | 0.1% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $31.65 | 0.1% | 2 | 2025 |
| Paragon 28, Inc. | Unresolved — no canonical attribution shown | $27.08 | 0.1% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $23.57 | 0.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.80 | 0.0% | 1 | 2025 |
| Orthofix Medical, Inc. | Unresolved — no canonical attribution shown | $22.14 | 0.0% | 1 | 2025 |
| Nexus Medical Technologies LLC | Unresolved — no canonical attribution shown | $20.44 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $42,647.31 | 14 |
| Travel and Lodging | $5,115.14 | 18 |
| Food and Beverage | $4,509.76 | 76 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,700.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LAPIPLASTY SYSTEM 1 Normalized: lapiplasty system 1 |
Device | TREACE MEDICAL CONCEPTS, INC. | $45,249.86 | 28 | 2025 |
Source payment records
|
|||||
| TMC PSI CUT GUIDE SYSTEM Normalized: tmc psi cut guide system |
Device | TREACE MEDICAL CONCEPTS, INC. | $1,281.51 | 8 | 2025 |
Source payment records
|
|||||
| PERCUPLASTY TRAY Normalized: percuplasty tray |
Device | TREACE MEDICAL CONCEPTS, INC. | $990.18 | 3 | 2025 |
Source payment records
|
|||||
| LAPIPLASTY Normalized: lapiplasty |
Device | TREACE MEDICAL CONCEPTS, INC. | $941.70 | 4 | 2025 |
Source payment records
|
|||||
| TMC SPEEDTMT Normalized: tmc speedtmt |
Device | TREACE MEDICAL CONCEPTS, INC. | $377.27 | 2 | 2025 |
Source payment records
|
|||||
| TMC NANOPLASTY SYSTEM Normalized: tmc nanoplasty system |
Device | TREACE MEDICAL CONCEPTS, INC. | $333.36 | 6 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $263.41 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $263.41 | 2 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $166.63 | 2 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $162.36 | 2 | 2025 |
Source payment records
|
|||||
| V.A.C.ULTA Normalized: v a c ulta |
Device | Solventum Corporation | $140.79 | 1 | 2025 |
Source payment records
|
|||||
| ALLOGRAFT WEDGE SYSTEM Normalized: allograft wedge system |
Device | TREACE MEDICAL CONCEPTS, INC. | $123.73 | 2 | 2025 |
Source payment records
|
|||||
| TMC SPEEDMTP Normalized: tmc speedmtp |
Device | TREACE MEDICAL CONCEPTS, INC. | $108.69 | 3 | 2025 |
Source payment records
|
|||||
| Biomet OrthoPak Non-invasive Bone Growth Stimulator System Normalized: biomet orthopak non invasive bone growth stimulator system |
Device | EBI, LLC | $86.22 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $85.89 | 4 | 2025 |
Source payment records
|
|||||
| CYGNUS DUAL Normalized: cygnus dual |
Medical Supply | Organogenesis Inc. | $39.80 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| INNOVABURN Normalized: innovaburn |
Device | ConvaTec Inc. | $34.71 | 1 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $34.71 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| Precision MIS Bunion Normalized: precision mis bunion |
Device | Paragon 28, Inc. | $27.08 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| Physio-Stim Normalized: physio stim |
Device | Orthofix Medical, Inc. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO Normalized: v a c veraflo |
Device | Solventum Corporation | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| SPEEDAKIN Normalized: speedakin |
Device | TREACE MEDICAL CONCEPTS, INC. | $8.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 133 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 105 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 21 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 29 |
| Terbinafine Hcl | Terbinafine Hcl | 33 | 17 |
| Ketoconazole | Ketoconazole | 32 | 17 |
| Ciclopirox | Ciclopirox | 29 | 17 |
| Ammonium Lactate | Ammonium Lactate | 28 | 12 |
| Cephalexin | Cephalexin | 24 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Mupirocin | Mupirocin | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $54,972.21 · 110 records | TREACE MEDICAL CONCEPTS, INC. | ACTIV.A.C., ALLOGRAFT WEDGE SYSTEM, Biomet OrthoPak Non-invasive Bone Growth Stimulator System, CYGNUS DUAL, Flexitouch Plus, INCEPTIV, INNOVABURN, INNOVAMATRIX AC, Kerecis GraftGuide, Kerecis SurgiClose, LAPIPLASTY, LAPIPLASTY SYSTEM 1, NUZYRA, Nimbl, PERCUPLASTY TRAY, PREVENA, PURIFIED CORTROPHIN GEL, Physio-Stim, Precision MIS Bunion, QUTENZA, SPEEDAKIN, TMC NANOPLASTY SYSTEM, TMC PSI CUT GUIDE SYSTEM, TMC SPEEDMTP, TMC SPEEDTMT, V.A.C. VERAFLO, V.A.C.ULTA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error